CLOROX CO /DE/
No SEC Form 4 filings for $CLX in the last 30 days.
See all $CLX insider activity →The article says The Clorox Company (CLX) shares have lagged the S&P 500 over 52 weeks, down 13.7% versus SPX up 20.6%. After Q4 2026 results on Aug. 3, CLX rose 6.5% on $1.95B sales and adjusted EPS $1.66, plus FY2027 net sales growth guidance of 13%-14%. Analysts: consensus Hold, JPMorgan raised PT to $95; stock trades above the mean $96.94, with a Street-high $117.
Clorox (CLX) reported Q4 FY2026 net sales of $1.95B, down 2% (GOJO added about 10 points). Organic sales fell 13% and adjusted EPS was $1.66, down 42%. Gross margin was 41.3%. For FY2027, it guided organic sales growth of 3.5% to 4.5% and adjusted EPS of $5.70 to $6.00, citing inflation headwinds of $200M+.
Clorox held its Q4 2026 earnings call, citing value-seeking consumer behavior and inflation pressures. Management said most categories have recovered from a prior cyberattack, with Litter still lagging. It highlighted GOJO acquisition synergies, fiscal 2027 assumptions including Brent at $90/bbl, inflation over $200M, and free cash flow of 11% to 13% of sales.
Over the past 7 days, alphai's AI scored 2 news stories mentioning CLX (CLOROX CO /DE/). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent CLX coverage spans earnings, financial news and sector analysis.
Post-earnings guidance and acquisition context shift the near-term earnings narrative, but gross margin deterioration and EPS outlook below some expectations temper upside.
Earnings call provides forward guidance and margin/cost drivers that can reset near-term expectations for CLX’s earnings power.
Guidance frames 2027 margin and cash-flow trajectory around GOJO integration, higher inflation costs, and ERP savings ramp timing.
The article frames CLX’s dividend safety and valuation around new fiscal 2027 guidance tied to the Gojo (Purell) acquisition and ERP optimization.
The outlook implies margin pressure and slower organic growth, shifting the risk balance toward downside if inflation or mix worsens.
alphai scores every news story that mentions CLX with an AI model for sentiment and relevance, and aggregates insider trades from CLOROX CO /DE/'s SEC EDGAR Form 4 filings. Figures refresh continuously.
The article says The Clorox Company (CLX) shares have lagged the S&P 500 over 52 weeks, down 13.7% versus SPX up 20.6%. After Q4 2026 results on Aug. 3, CLX rose 6.5% on $1.95B sales and adjusted EPS $1.66, plus FY2027 net sales growth guidance of 13%-14%. Analysts: consensus Hold, JPMorgan raised PT to $95; stock trades above the mean $96.94, with a Street-high $117.
6 min readClorox (CLX) reported Q4 FY2026 net sales of $1.95B, down 2% (GOJO added about 10 points). Organic sales fell 13% and adjusted EPS was $1.66, down 42%. Gross margin was 41.3%. For FY2027, it guided organic sales growth of 3.5% to 4.5% and adjusted EPS of $5.70 to $6.00, citing inflation headwinds of $200M+.
6 min readClorox held its Q4 2026 earnings call, citing value-seeking consumer behavior and inflation pressures. Management said most categories have recovered from a prior cyberattack, with Litter still lagging. It highlighted GOJO acquisition synergies, fiscal 2027 assumptions including Brent at $90/bbl, inflation over $200M, and free cash flow of 11% to 13% of sales.
7 min readClorox (CLX) completed its April 1 acquisition of Gojo Industries, adding Purell, which now drives more than half of net sales. For fiscal 2027, Clorox guides net sales up 13% to 14% and adjusted EPS of $5.70 to $6.00. It also raised its quarterly dividend to $1.25 and expects FCF at 11% to 13% of net sales.
6 min readClorox forecast a difficult fiscal 2027, citing inflation and consumers shifting to value. The company expects net sales up 13% to 14% for fiscal 2027, with about 9.5 points from its April 2026 GOJO Industries acquisition. Adjusted EPS is projected at $5.70 to $6.00, GAAP diluted EPS $5.41 to $5.71. Q4 revenue fell 2% to $1.95B; adjusted EPS was $1.66.
4 min readTD Cowen said Big Food categories have held up versus external factors such as GLP-1 drugs, MAHA, and SNAP cuts, but companies are losing share to premium and private-label brands. It flagged Hershey (3.7% YTD vs 4.8% category), McCormick (0.2% vs 3.2%), and others, citing margin and share risks including Conagra’s pricing and Kraft Heinz’s weak categories.
6 min readClorox (CLX) reported lower Q4 and FY2026 profit, citing year-over-year sales declines. The company posted non-GAAP EPS of $1.66 for the quarter, slightly above estimates, and revenue of $1.95B, above expectations, according to the article.
2 min readClorox (NYSE:CLX) reported Q2 CY2026 sales of $1.95 billion, down 2% year on year but 2.6% above analysts’ revenue expectations. Non-GAAP EPS was $1.66, 0.9% above consensus. The article also cites trailing 12-month revenue of $6.72 billion and notes full-year EPS guidance missed estimates.
5 min readReuters reports Clorox (Pine-Sol maker) forecast fiscal 2027 net sales growth of 13% to 14%, above analysts’ 12.8% estimate, and adjusted EPS of $5.70 to $6 versus $5.97 expected. Q4 sales fell 2% to $1.95B but beat $1.90B. Gross margin dropped to 41.3%. Clorox cited improving demand amid a challenging cost and value-seeking environment.
3 min readCLOROX CO /DE/ (CLX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex991-pressreleasedatedaug.htm EX-99.1 Document Clorox Reports Q4 and FY26 Results, Provides FY27 Outlook Delivers Q4 results in line with expectations while advancing strategic investments OAKLAND, California, Aug. 3, 2026 — The Clorox Company (NYSE: CLX) today reporte
7 min read
